AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reiterated by FBR & Co in a report issued on Saturday. They currently have a $3.00 price target on the biopharmaceutical company’s stock. FBR & Co’s target price suggests a potential upside of 417.15% from the company’s current price.

Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.6780% during mid-day trading on Friday, hitting $0.5801. 469,257 shares of the stock traded hands. The stock has a 50-day moving average of $0.72 and a 200-day moving average of $0.68. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $1.15. The company’s market cap is $44.01 million.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/04/21/aveo-pharmaceuticals-aveo-outperform-rating-reaffirmed-at-fbr-co-updated-updated.html.

In other news, major shareholder Equity Opportunities Iv Growth acquired 6,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The stock was acquired at an average cost of $0.50 per share, with a total value of $3,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.10% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of AVEO. Sarissa Capital Management LP bought a new stake in shares of AVEO Pharmaceuticals during the fourth quarter worth $917,000. New Leaf Venture Partners L.L.C. bought a new stake in shares of AVEO Pharmaceuticals during the fourth quarter worth $1,399,000. Renaissance Technologies LLC increased its stake in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock worth $1,482,000 after buying an additional 148,500 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in AVEO Pharmaceuticals during the fourth quarter worth approximately $1,678,000. 37.94% of the stock is owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

5 Day Chart for NASDAQ:AVEO

Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.